Tüdőrák: vizsgálatok itt: Németország
182 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 18.. Ask the study team whether a trial fits you.
- No phaseNot yet taking people in NémetországImpact of a Reminder App on Physical Activity During Radiation Therapy for Lung Cancer
- Where
- Hanover, Kiel, Lübeck
- Életkor
- 18 év and over
- People
- 32 worldwide
- Run by
- University Hospital Schleswig-Holstein
See details and how to joinNCT07627022 - 2. fázisTaking peopleNiraparib Added to Anti-PD-L1 Antibody Maintenance in SLFN11-positive, Extensive-disease SCLC
- Where
- Munich
- Életkor
- 18 év and over
- People
- 44 worldwide
- Run by
- ETOP IBCSG Partners Foundation
See details and how to joinNCT05718323 · EU 2022-502092-33-00 - 1/2. fázisFut, nem toborozA Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
- Where
- Dresden, Heidelberg
- Életkor
- 12 év and over
- People
- 500 worldwide
- Run by
- Turning Point Therapeutics, Inc.
See details and how to joinNCT03093116 · EU 2024-512606-25-00 - 3. fázisNot yet taking people in NémetországPhase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)
- Where
- Berlin, Giessen, Heidelberg, Munich, Oldenburg
- Életkor
- 18 év and over
- People
- 180 worldwide
- Run by
- Nuvation Bio Inc.
See details and how to joinNCT07154706 · EU 2025-521971-29-00 - 1. fázisTaking peoplePhase I open-label, multi-center study to evaluate the safety, tolerability, dosimetry, and preliminary activity of [177Lu]Lu-NNS309 in patients with pancreatic, lung, breast and colorectal cancers.
- Where
- Cologne, Essen, Munich, Rostock
- Életkor
- 18 év and over
- People
- 76 worldwide
- Run by
- Novartis Pharma AG
See details and how to join2023-510356-23-00 - No phaseTaking peopleReal-World Data on the Treatment of Lung Cancer Patients With the Immune-Checkpoint Inhibitor Tislelizumab
- Where
- Frankfurt am Main
- Életkor
- 18 év and over
- People
- 240 worldwide
- Run by
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
See details and how to joinNCT07510724 - 2. fázisTaking peopleOsimertinib plus chemotherapy as 1st line therapy in stage IV NSCLC patients with atypical EGFR mutations (AIO-TRK/YMO-0324)
- Where
- Berlin, Cologne, Dresden, Duesseldorf, Esslingen am Neckar, Frankfurt am Main, Frankfurt Am Main, Georgsmarienhuette, Giessen, Goettingen, Grosshansdorf, Hemer, Kiel, Mannheim, Munich, Offenbach Am Main, Oldenburg, Tuebingen
- Életkor
- 18 év and over
- People
- 40
- Run by
- Universitat Heidelberg
See details and how to join2024-516790-78-00 - No phaseTaking peopleThe CyberChallenge Trial How Much is Too Much - What is the Role of Cyberknife Radiosurgery in Patients With Multiple Brain Metastases?
- Where
- Heidelberg
- Életkor
- 18 év and over
- People
- 190
- Run by
- University Hospital Heidelberg
See details and how to joinNCT05378633 - No phaseTaking peopleThe MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study
- Where
- Tübingen
- Életkor
- 18 év and over
- People
- 8000 worldwide
- Run by
- UMC Utrecht
See details and how to joinNCT04075305 - 2. fázisTaking peopleImmunochemotherapy, Surgery or Chemoradiation, and Durvalumab for Stage IIIA/B NSCLC
- Where
- Bonn, Freiburg im Breisgau, Giessen, Leipzig, Minden, Stuttgart, Troisdorf
- Életkor
- 18 év to 74 év
- People
- 176
- Run by
- University Hospital, Bonn
See details and how to joinNCT06810609 · EU 2024-516367-80-00 - No phaseTaking peopleUrolithin A in Patients With Previously Untreated Solid Tumors Receiving Immune Checkpoint Inhibitors
- Where
- Frankfurt
- Életkor
- 18 év and over
- People
- 45
- Run by
- Goethe University
See details and how to joinNCT07161310 - No phaseTaking peopleRisk Factors for Neuroendocrine Neoplasms
- Where
- Nuremberg
- People
- 14 250
- Run by
- Bavarian Cancer Registry
See details and how to joinNCT06282016 - 2. fázisTaking peoplePACCELIO - FDG-PET Based Small Volume Accelerated Immuno Chemoradiotherapy in Locally Advanced NSCLC
- Where
- Bonn, Dresden, Freiburg im Breisgau, Goettingen, Homburg, Moenchengladbach, Munich, Stuttgart, Troisdorf
- Életkor
- 18 év and over
- People
- 110 worldwide
- Run by
- TheraOp
See details and how to joinNCT06102057 · EU 2023-510506-41-00 - No phaseNot yet taking people in NémetországNeutrophil Biomarker Test for Predicting Clinical Benefit From Immunotherapy Based on Flow Cytometry Analysis
- Where
- Heidelberg
- Életkor
- 18 év and over
- People
- 600 worldwide
- Run by
- OncoHost Ltd.
See details and how to joinNCT07246759 - No phaseNot yet taking people in NémetországImmune-Marker Platform for Patients With Advanced Lung Cancer
- Where
- Cologne, Dresden
- Életkor
- 18 év and over
- People
- 500
- Run by
- Technische Universität Dresden
See details and how to joinNCT07150598 - 2. fázisTaking peoplePreoperative Amivantamab or Amivantamab and Carboplatin/Pemetrexed Treatment in Patients With Resectable Non-small-cell Lung Cancer Harboring Oncogenic EGFR Mutations (NEOpredict-EGFR)
- Where
- Essen, Heidelberg
- Életkor
- 18 év and over
- People
- 20 worldwide
- Run by
- University Hospital, Essen
See details and how to joinNCT06784791 · EU 2023-505662-28-00 - 1/2. fázisTaking peopleFIH Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors With MET Alterations
- Where
- Cologne, Dresden
- Életkor
- 18 év and over
- People
- 140 worldwide
- Run by
- Pierre Fabre Medicament
See details and how to joinNCT06669117 · EU 2024-512760-64-00 - No phaseNot yet taking people in NémetországRadiation-induced Toxicity of the Heart
- Where
- Dresden
- Életkor
- 18 év and over
- People
- 325
- Run by
- Technische Universität Dresden
See details and how to joinNCT06986291 - 2. fázisTaking peopleMaintenance Durvalumab (MEDI4736) and Olaparib (AZD2281) After Standard 1st Line Treatment (Carboplatin/Cisplatin, Etoposide, Durvalumab) in HRD Positive Extensive Disease (ED) Small-cell Lung Cancer (SCLC)
- Where
- Berlin, Cologne, Heidelberg, Hemer, Oldenburg
- Életkor
- 18 év to 120 év
- People
- 29
- Run by
- University of Cologne
See details and how to joinNCT06419179 · EU 2024-512373-27-00 - No phaseTaking peoplePredicting Cancer Risk With Digital and Molecular Markers
- Where
- Please Refer to Project Homepage For Details (see Link Below)
- Életkor
- 18 év and over
- People
- 1250
- Run by
- University of Erlangen-Nürnberg Medical School
See details and how to joinNCT06962670 - No phaseTaking peopleGiessen Pulmonary Hypertension in Lung Cancer Registry
- Where
- Giessen
- Életkor
- 18 év and over
- People
- 500
- Run by
- University of Giessen
See details and how to joinNCT04467333 - No phaseNot yet taking people in NémetországClinical Validation and Benchmarking of Top Performing ctDNA Diagnostics - Stage III NSCLC
- Where
- Großhansdorf
- Életkor
- 18 év and over
- People
- 248 worldwide
- Run by
- University Medical Center Groningen
See details and how to joinNCT06111807 - 2. fázisTaking peopleAdditional Chemotherapy for EGFRm Patients with the Continued Presence of Plasma CtDNA EGFRm At Week 3 After Start of Osimertinib 1st-line Treatment (PACE-LUNG)
- Where
- Berlin, Cologne, Dresden, Essen, Frankfurt, Gauting, Georgsmarienhütte, Göttingen, Halle, Hamburg, Heidelberg, Hemer, Mainz, München, Nuremberg, Oldenburg
- Életkor
- 18 év and over
- People
- 50
- Run by
- Goethe University
See details and how to joinNCT05281406 - No phaseTaking peopleImprovement of Quality of Life (QoL) Using Preference-Oriented QoLMonitoring in Patients with Lung Cancer
- Where
- Bamberg, Bayreuth, Coburg, Donaustauf, Kulmbach, Regensburg, Straubing
- Életkor
- 18 év and over
- People
- 220
- Run by
- University of Bayreuth
See details and how to joinNCT06252233 - 2. fázisTaking peoplePredicting Response to Neoadjuvant ATEZOLIZUMAB Plus Carboplatin/Nab Paclitaxel in Resectable Non-squamous NSCLC
- Where
- Heidelberg
- Életkor
- 18 év and over
- People
- 20
- Run by
- University Hospital Heidelberg
See details and how to joinNCT04865250